Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits

International Journal of Tissue Reactions

Volumn 25, Issue 3, 2003, Pages 81-89

  Mendoza, S ^a   Gamez, R ^a   Mas, R ^a   Goicochea, E ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPHATIC CARBOXYLIC ACID; CHOLESTEROL; D 003; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MIXTURE; FOOD INTAKE; HEALTH STATUS; LIPID BLOOD LEVEL; MALE; MONOTHERAPY; NONHUMAN; RABBIT; RANDOMIZATION; STATISTICAL ANALYSIS; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FATTY ACIDS; FATTY ACIDS, MONOUNSATURATED; INDOLES; LIPIDS; LIPOPROTEINS, LDL; MALE; RABBITS; TRIGLYCERIDES;

ANIMALIA; ARUNDINARIA; ORYCTOLAGUS CUNICULUS; SACCHARUM;

EID: 0347316393     PISSN: 02500868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA, 251(3), 351, 1984.
2. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to colesterol lowering. JAMA, 251(3), 365, 1984.
3. Iso, H., Jacobs, D.R. Jr., Wentworth, D., Neaton, J.D., Cohen, J.D. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N. Engl. J. Med., 320(14), 904, 1989.
4. Frick, M.H., Elo, O., Happa, K., et al. Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med., 317(20), 1237, 1987.
5. Pyorala, K., De Backer, G., Graham, I., et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur. Heart J., 15, 1300, 1994.
6. Gotto, A.M., Assman, G., Carmena, R., Davignon, J., et al. The ILIB Lipid Handbook for Clinical Practice. Blood Lipids and Coronary Heart Disease. Second Edition, International Lipid Information Bureau (ILIB), New York, 2000.
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383, 1994.
8. Sacks, F.M., Pfeffer, M.A., Moye, L.A., et al. for the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 335, 1001, 1996.
9. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 339, 1349, 1998.
10. Shepherd, S., Cobbe, S.M., Ford, I., et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med., 333, 1301, 1995.
11. Downs, J.R., Clearfield, M., Weiss, S., et al. for the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA, 279, 1615, 1998.
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet, 360, 7, 2002.
13. Shepherd, J., Blauw, G.J., Murphy, M.B., et al., on behalf of the PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled study. Lancet, 360, 1623, 2002.
14. González L., Marrero D., Laguna A., et al. inventors; Laboratorios Dalmer SA, assignee: Mixture of primary fatty acids of high molecular weight obtained from sugar cane wax and its pharmaceutical uses. Republic of South Africa patent 98-2744. December 30, 1998.
15. Gámez, R., Mendoza, S., Más, R., et al. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr. Ther. Res. Clin. Exp., 61, 8, 2000.
16. Mendoza S., Gámez R., Noa M., et al. The effects of D-003 and policosanol on the lipid profile and endothelial cells in normocholesterolemic rabbits: A head-to-head comparison. Curr. Ther. Res. Clin. Exp., 62, 209, 2001.
17. Gámez, R., Mendoza, S., Mas, R., et al. Comparison of the cholesterol-lowering effects and toxicity of D-003 and lovastatin on normocholesterolemic rabbits. Drugs R&D, 4, 219, 2003.
18. Menéndez, R., Mas, R., Amor, A.M., et al. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids. Pharmacol. Res., 44(4), 299, 2001.
19. Castaño, G., Mas, R., Fernáandez, L., Illnait, J., et al. Assessment of the effects of D-003, a new antiplatelet and hypocholesterolemic compound on healthy volunteers: A phase I clinical study. Drugs R&D, 3, 337, 2002.
20. Arruzazabala, M.L., Carbajal, D., Más, R., et al. Effects of D-003, a new compound purified from sugar cane was, on platelet aggregation in healthy volunteers: A randomized, double-blinded clinical study. Clin. Drug Invest., 23, 107, 2002.
21. Castaño, G., Menéndez, R., Mas, R., et al. Effects of D-003 on lipid profile and lipid peroxidation in healthy volunteers. Clin. Drug Invest., 23, 193, 2003.
22. Gámez, R., Más, R., Noa, M., et al. Acute and subchronic oral toxicity of D-003 in rats. Toxicol. Lett., 118, 31, 2000.
23. Gámez, R., Mas, R., Noa, M., et al. Six-month toxicity study of oral administration of D-003 in Sprague Dawley rats. Drugs R&D, 3, 375, 2002.
24. Gámez, R., González, J.E., Rodeiro, I., et al. In vivo genotoxic evaluation of D-003, a mixture of very long-chain aliphatic acids. J. Med. Food, 4, 85, 2001.
25. Gámez, R., Rodeiro, I., Fernández, I., Acosta, P.C. A preliminary evaluation of the cytotoxic and genotoxic potential of D-003: A mixture of very long chain fatty acids. Teratogen, Carcinogen, Mutagen, 22, 175-181, 2002.
26. Plosker, G.L., Wagstaff, A.J. Fluvastatin: A review of its pharmacology and use in the management of hypercholesterolaemia. Drugs, 51, 433, 1996.
27. Seigler, L., Wu, W.T. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin. Chem., 27, 838, 1981.
28. Friedewald, W.T., Levy, I.R., Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 18, 499, 1972.
29. McCarthy, P.A. New approaches in atherosclerosis: An overview. Med. Res. Rev., 2, 139, 1993.
30. Kroon, PA., Hand, KH., Jesse, W.H., Alberts, A.W. The effects of mevinolin on serum cholesterol levels of rabbits with endogenous hypercholesterolemia. Atherosclerosis, 44, 41, 1982.
31. Chao, Y.S., Kroon, P.A., Yamin, T.T., Thompson, G.M, Albets A.W. Regulation of hepatic receptor-dependent dependent degradation of LDL by mevinolin in rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Biochim. Biophys. Acta., 754, 134, 1983.
32. Chao, Y.S., Yamin, T.T., Seidenberg, J., Kroon, P.A. Secretion of cholesterol-ester-rich lipoprotein by the perfused livers of rabbits fed a wheat-starch casein diet. Biochim. Biophys. Acta., 876, 392, 1986.